Drug intelligence / Profile preview

SSS55

Development stage: Phase 1
Lead developer: Shenyang Sunshine Pharmaceuticals
Administration: Intravenous

Overview

SSS55 is a biological product developed by Shenyang Sunshine Pharmaceuticals. It is currently in Phase 1 clinical trials, primarily evaluated as an injectable formulation. The initial indications under investigation are paroxysmal hemoglobinuria (a rare blood disorder) and nephrosis (a kidney condition). The specific mechanism of action and molecular target have not been disclosed in public sources as of the most recent updates.

Other names: SSS55SSS-55SSS 55

Targets

C3b (Complement Component 3b)

Beyond the preview

Go deeper on SSS55.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SSS55.

Explore the full profile